A phase I study of the human anti‐activin receptor‐like kinase 1 antibody PF‐03446962 in Asian patients with advanced solid tumors

Preclinical studies suggest that ALK‐1 signaling mediates a complementary angiogenesis pathway activated upon development of resistance to vascular endothelial growth factor (VEGF)‐targeted therapies. Inhibition of ALK‐1 signaling may lead to disruption of tumor angiogenesis and growth. We report fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Doi, Toshihiko, Lee, Kyung‐Hun, Kim, Tae‐Min, Ohtsu, Atsushi, Kim, Tae Yong, Ikeda, Masafumi, Yoh, Kiyotaka, Gallo Stampino, Corrado, Hirohashi, Tomoko, Suzuki, Akiyuki, Fujii, Yosuke, Andrew Williams, James, Bang, Yung‐Jue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944871/
https://www.ncbi.nlm.nih.gov/pubmed/27075560
http://dx.doi.org/10.1002/cam4.724

Ejemplares similares

Ejemplares similares